Appearing as a noteworthy development in the battle against obesity, this medication is generating considerable buzz. This treatment combines properties of two established GLP-1 receptor agonists, liraglutide, plus an unique website glucose-dependent peptide component. Early patient results have shown significant body reduction in patients with a